John FahyFounder

United States - San Francisco, California

Dr Fahy is Professor of Medicine and the Michael S. Stulbarg Endowed Chair in Pulmonary Medicine at the University of California San Francisco (UCSF) where he leads clinical and research programs in asthma and other diseases of the airways (bronchial tubes). He directs the UCSF faculty practice in severe asthma and the UCSF Airway Clinical Research Center. Professor Fahy's research program involves clinical and bench laboratory research in asthma and other airway diseases and his program has been continuously funded by the National Institutes of Health (NIH) for 25 years. He has led UCSF centers in multicenter clinical research initiatives in asthma funded by the National Institutes of Health (NIH), including the Severe Asthma Research Program (SARP) and the Precision Interventions for Severe Asthma (Precise). His research group has a longstanding focus on airway mucus pathology and his group's research has identified mechanisms of mucus pathology that provide clues for treatment. Recently he collaborated with Stefan Oscarson at University College Dublin and Anne Marie Healy at Trinity College Dublin to develop a novel inhaled (mucolytic) drug that breaks up mucus in the lungs, and he founded Aer Therapeutics to advance this mucolytic drug technology to the clinic. Professor Fahy has been recognized multiple times for his clinical and scientific excellence, including election to the American Association of Physicians in 2016, awards for scientific accomplishment from the American Thoracic Society in 2015 and 2017 and from the European Respiratory Society (ERS) in 2019 (Gold Medal in Asthma). And in 2020 he was the recipient of the tenth annual UCSF Faculty Research Lecture in Translational Science.